Table 1.

Country malaria treatment policy contexts and status of PDMC policy adoption

Uganda
Treatment policy	1st line treatment for uncomplicated malaria   Artemether-lumefantrine (AL)   Alternative 1st line treatment is Artesunate-amodiaquine (AS-AQ) 2nd line treatment for uncomplicated malaria   Dihydroartemisinin-piperaquine (DP) Severe malaria a) At health facility level:   IV artesunate   Dihydroartemisinin-piperaquine to be administered at discharge b) Pre-referral treatment at community and lower-level health facilities   Rectal artesunate, then continue as in (a) above
PDMC policy adoption status	MoH has recommended adoption of WHO guidelines on PDMC
Malawi
Treatment policy	1st line treatment for uncomplicated malaria   Artemether-lumefantrine (AL)   Dihydroartemisinin-piperaquine (DP) is set to replace AL as first line treatment but has not yet been rolled-out 2nd line treatment for uncomplicated malaria   Artesunate-amodiaquine (AS-AQ) Severe malaria   IV artesunate   Dihydroartemisinin-piperaquine to be administered at discharge
PDMC policy adoption status	Evidence has been presented to Technical Working Group (TWG) (including case management) and Malaria Advisory Committee MoH has asked Health Service Delivery TWG to review results prior to giving policy approval
Kenya
Treatment policy	1st line treatment for uncomplicated malaria   Artemether-lumefantrine (AL)   No planned changes to first line treatment choice 2nd line treatment for uncomplicated malaria   Dihydroartemisinin-piperaquine (DP) Severe malaria   IV artesunate   Artemether-lumefantrine to be administered at discharge
PDMC policy adoption status	Policy adoption of PDMC has not yet been initiated Stakeholder engagement has commenced
Benin
Treatment policy	1st line treatment for uncomplicated malaria   Artemether-lumefantrine (AL)   Dihydroartemisinin-piperaquine (DP) is used in private facilities but is not available in the public system 2nd line treatment for uncomplicated malaria   Pyronaridine-artesunate (AP) but not yet in the supply chain Severe malaria   IV artesunate   Artemether-lumefantrine to be administered at discharge
PDMC policy adoption status	Policy adoption of PDMC has not yet been initiated Stakeholder engagement has commenced